Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

✍ Scribed by I. Vergote; N. Finkler; J. del Campo; A. Lohr; J. Hunter; D. Matei; J. Kavanagh; J.B. Vermorken; L. Meng; M. Jones; G. Brown; S. Kaye

• Book ID: 116430077
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 317 KB
• Volume: 45
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/j.ejca.2009.05.016